S-1-Induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5′-DFUR: A case report with pharmacokinetic study

Japanese Journal of Clinical Oncology

Volumn 34, Issue 5, 2004, Pages 282-286

  Ueda, Yuji ^a   Yamagishi, Hisakazu ^a   Yamashita, Tetsuro ^a   Itoh, Norio ^a   Itoi, Hirosumi ^a   Shirasaka, Tetsuhiko ^b   Ajani, Jaffer A ^c  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Complete response; Gastric cancer; Lung metastasis; Pharmacokinetic study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXIFLURIDINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; TS 1; ANTINEOPLASTIC ANTIMETABOLITE; FLOXURIDINE; OXONIC ACID; PYRIDINE DERIVATIVE; S 1 (COMBINATION); TEGAFUR;

ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER REGRESSION; CASE REPORT; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; LUNG METASTASIS; LUNG RESECTION; POSTOPERATIVE CARE; PREOPERATIVE CARE; STOMACH CANCER; ADJUVANT CHEMOTHERAPY; BLOOD; COLLOID CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG ADMINISTRATION; DRUG COMBINATION; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; REMISSION; STOMACH TUMOR; THORAX RADIOGRAPHY;

ADENOCARCINOMA, MUCINOUS; ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ESOPHAGECTOMY; FEMALE; FLOXURIDINE; FLUOROURACIL; GASTRECTOMY; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; OXONIC ACID; PYRIDINES; RADIOGRAPHY, THORACIC; REMISSION INDUCTION; STOMACH NEOPLASMS; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 3342959868     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh044     Document Type: Article

References (16)

1. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulation. Anticancer Drugs 1996;7: 548-57.
2. Diasio RB. Clinical implication of dihydropyrimidine, dehydrogenase inhibition. Oncology 1999;13(Suppl 3):17-21.
3. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-6.
4. Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil anti-tumor drug. Clin Cancer Res 1999;5:2000-5.
5. Sakata, Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M otastat potassium) in advanced gastric cancer patients. Ear J Cancer 1998;34:1715-20.
6. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S- 1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
7. Maehara Y. S-1 in gastric cancer: A comprehensive review. Gastric Cancer 2003;6(Suppl 1):2-8.
8. Matsushima E, Yoshida K, Kitamura R, Yoshida K. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypydmidine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B 1997; 691:95-104.
9. Ajani JA. Chemotherapy for gastric carcinoma: New and old options. Oncology 1998;12:44-7.
10. Kurimoto N, Yasuzawa Y, Itoh N, Tamura T, Yoshimoto I. A case report: 5′-DFUR reduced multiple liver metastases of gastric cancer. Gan To Kagaku Ryoho 1992;19:1067-70 (in Japanese).
11. Miyoshi K, Matsui T, Gangi J, Shinoura S, Sezaki N. A case report of advanced gastric cancer that responded to long-term administration of low-dose 5′-DFUR. Gan To Kagaku Ryoho 1997;24:101-3 (in Japanese).
12. Takiguchi N, Nakajima N, Saitoh N, Fujimoto S, Nakazato H. A phase III randomized study comparing oral 5-fluorouracil after curative resection of gastric cancer. Int J Oncol 2000;16:1021-7.
13. Boku N, Ohtsu A, Shimada, Y Shirao K, Seki S, Saitoh H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
14. Takahashi K, Miyagawa K, Mitachi Y, Matsuda T, Oogoshi T. A case of gastric cancer with metastasis to cervical lymph node and pulmonary lymphangitis carcinomatosa responding to neoadjuvant chemotherapy with S-1 and CDDP. Gan To Kagaku Ryoho 2003;30:685-9 (in Japanese).
15. Nakamura T, Yamasaki K, Morikawa S, Ohnita T, Tanta K, Isomoto H, et al. A case report of advanced gastric cancer responding to TS-1, a novel oral fluorouracil derivative. Gan To Kagaku Ryoho 2002;29:927-32 (in Japanese).
16. Tsukioka Y, Matsumura Y, Hamaguchi T, Goto M, Muro K, Yamada Y, et al. Complete response achieved following administration of S-1 in patient with adrenal gland metastasis of 5-FU resistant gastric cancer: A case report. Jpn J Clin Oncol 2001;31:450-3.